Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 21, 2017
Pharmacy Choice - News - Pharmaceutical Development - September 21, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/22/17 - Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial [Syrian Arab News Agency]
Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug application to the U.S Food and Drug Administration for NasoVAX, the Companys intranasally administered recombinant flu vaccine. Sybil Tasker, Chief Medical Officer at Altimmune. Current vaccines leave significant room
8/22/17 - Aurobindo Pharma gets USFDA nod for anti-HIV drug [Arab News (Saudi Arabia)]
Aurobindo Pharma has received tentative approval from the USFDA for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, used for the treatment of HIV, in the US market. In a BSE filing, Aurobindo Pharma said it has received "tentative approval from the US Food and Drug Administration under the US President`s Emergency Plan For AIDS
8/22/17 - CHRISTUS Health Joins TriNetX Health Research Network to Accelerate Clinical Trial Efforts [Sudan Tribune]
CHRISTUS Health, one of the top ten largest Catholic health systems in the U. S., has signed on to the TriNetX global health research network, TriNetX announced today. CHRISTUS Health has decided to standardize on the TriNetX network as their conduit to sponsored clinical trials. "CHRISTUS Health`s partnership with TriNetX will enhance our clinica
8/22/17 - Contract Research Organizations (CROs) Services Global Market 2017 Share, Trend, Segmentation and Forecast to 2022
PUNE, INDIA, August 22, 2017/ EINPresswire.com/ Global Contract Research Organizations Services Market This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Contract R
8/22/17 - CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV [T-break Tech (Middle East)]
CytoDyn Inc., a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus infection, announces that the Company has enrolled 34 patients in its pivotal Phase 2 b/3 trial of PRO 140 in combination with antiretroviral therapy in HIV-infected patients. Thirty-three of the enrolled patients ha
8/22/17 - FDA Approves IRWD's Gout Drug, It's A Thumbs Up For ALXN In EU, CRME Crushed
TOKYO- Today's Daily Dose brings you news about European approval of Alexion' s Soliris for an additional indication; Alkermes' New Drug Application for a major depressive disorder drug; Astellas' MORPHO trial progress; Axovant's move to NASDAQ from the Big Board; Cardiome's disappointing update related to its antiarrhythmic drug and FDA approval o
8/22/17 - Findings from National Taiwan University Hospital in Clinical Trials and Studies Reported (Right or left? Side selection for a totally implantable...
Findings from National Taiwan University Hospital in Clinical Trials and Studies Reported. By a News Reporter-Staff News Editor at Cancer Weekly Investigators publish new report on Clinical Research- Clinical Trials and Studies. Our news journalists obtained a quote from the research from National Taiwan University Hospital, "We enrolled patients
8/22/17 - Funding Available in Cooperative Agreement for Existing Therapeutics Studies
The U.S. Department of Health and Human Services' National Institutes of Health announced that it expects to award a cooperative agreement for supporting pre-clinical studies to repurpose existing FDA approved therapeutics that have already begun or completed at least a Phase l trial. This funding opportunity is open to state, county, city, townshi
8/22/17 - Global Dilated Cardiomyopathy Therapeutics Market by Analysis of Major Industry Segments 2014 - 2020
Transparency Market Research Report Added "Dilated Cardiomyopathy Therapeutics Market- Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014- 2020" Albany, NY 08/21/2017 Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expecte
8/22/17 - Lotus Clinical Research Executive to Present on Opioid Sparing Endpoints at 11th Annual Pain & Migraine Therapeutics Summit
Neil Singla, Chief Scientific Officer of Lotus Clinical Research will discuss these endpoints and criteria for submission of opioid-sparing labels to the FDA at the 11th Annual Pain and Migraine Therapeutics Summit, taking place in San Diego, CA on September 27-28, 2017. Dr. Singla will outline the regulatory criteria required when seeking an...
8/22/17 - Lynparza approval sets up tighter bout with PARP rivals [T-break Tech (Middle East)]
The FDA has also finalised an earlier conditional approval of Lynparza in BRCA-positive patients who have been treated with three or more lines of chemotherapy. That nullifies a big competitive edge for Tesaro`s drug that were a factor in analysts predicting rapid sales gains to $1 bn- plus. AZ has just enhanced its position in the three-way battle
8/22/17 - MatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic Dermatitis [Syrian Arab News Agency]
-MatriSys Bioscience, a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, today announced that the first patient has been dosed in a Phase 2 A clinical study of an investigational therapy in adults with moderate-to-severe atopic dermatitis. This Atopic Dermatitis Research Network led study is sponsored by th
8/22/17 - Ovid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies [Tehran Times (Iran)]
Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced it has randomized the first patient in its Phase 1 b/2a clinical trial of TAK-935, also known as OV935, in collaboration with Takeda Pharmaceutical Company Limited. Emiliangelo Ratti, head of Takedas..
8/22/17 - Pfizers Besponsa gets FDA approval for treatment of B-cell precursor ALL [Algeria Press Service]
Developed jointly by Pfizer and Celltech, now known as UCB, Besponsa is an antibody-drug conjugate made up of a monoclonal antibody targeting CD22, a cell-surface antigen expressed on cancer cells in almost all B-ALL patients linked to a cytotoxic agent. Pfizer oncology global president Liz Barrett said: The approval of Besponsa is an important ste
8/22/17 - Purdue Scientist Receives $1.6 Million Grant on Repurposed Drugs As Treatment
Purdue University issued the following news release:. A Purdue University researcher has been awarded a $1.6 million grant from the National Institutes of Health to further study whether two FDA- approved drugs can be repurposed to treat life-threatening drug-resistant bacteria. The Centers for Disease Control and Prevention reports at least 2 mill
8/22/17 - Samsung Bioepis, Takeda agree to develop biosimilar drugs [Arab Finance (Egypt)]
Samsung Bioepis and Takeda Pharmaceutical have signed a strategic collaboration agreement to develop new biopharmaceuticals, Samsung Bioepis said Monday. Takeda Pharmaceutical also showed enthusiasm for the cooperative agreement. The company is collaborating with Merck, a global Pharmaceutical company, also known as MSD in Korea.
8/22/17 - Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients
Sensorion, a biotech company pioneering novel treatments of inner ear diseases, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to SENS-401, a therapy in development for the treatment of hearing disorders, for the prevention of Platinum-Induced Ototoxicity in pediatric patients. Nawal Ouzren, CEO of Se
8/22/17 - Sparks Gene Therapy SPK-8011 to Treat Hemophilia A and B Advance in Clinical Trials [Syrian Arab News Agency]
Three patients who received SPK-8011 a gene therapy developed by Spark Therapeutics for hemophilia A show increased production of clotting factor VIII without any safety issues reported, says the company. The patients are the first to receive the treatment as part of a Phase 1/ 2 clinical trial, with early data showing they have not yet experienced
8/22/17 - Studies from Saitama Medical University International Medical Center Further Understanding of Solid Cancer (Phase 1 dose-escalation study of...
By a News Reporter-Staff News Editor at China Weekly News Research findings on Oncology- Solid Cancer are discussed in a new report. According to news reporting originating in Saitama, Japan, by VerticalNews journalists, research stated, "Veliparib is a potent, orally bioavailable poly polymerase-1 and -2 inhibitor. The news reporters obtained a
8/22/17 - Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML [Syrian Arab News Agency]
Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia. The FDAs Office of Orphan Drug Products...
8/22/17 - Trovagene`s PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines [Syrian Arab News Agency]
Trovagene, Inc., a precision medicine biotechnology company, today announced compelling results of preclinical research of PCM-075 with a Histone deacetylase inhibitor in Non-Hodgkin Lymphoma cell lines. Steven Grant, Associate Director for Translational Research and co-Leader, Developmental Therapeutics Program, Massey Cancer Center.
8/22/17 - US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma [T-break Tech (Middle East)]
US FDA has granted two orphan drug designations for T cell therapy products to Singapore- based biotech company, Lion TCR Pte Ltd, for the treatment of hepatocellular carcinoma. HCC is the world`s third leading cause of death due to cancer and the second for China. Globally, 60% of HCC is a result of chronic hepatitis B infection, for the case of C
8/22/17 - Vascular Dynamics, a Part of the Rainbow Medical Investment Cluster, Received FDA Approval to Begin Conclusive and Pivotal Trial Experimentation for Their Flagship Product Designed to Treat Chronic Hypertension
Vascular Dynamics was chosen by the FDA to participate in an accelerated EAP program, the objective of which is to catalyze innovative and life-saving experimental treatments, as a means of bringing them to clinical use among patients as soon as possible. In addition, the company is one of nine companies chosen for participation in an IDE pilot pro
8/21/17 - "Dermal Filler" in Patent Application Approval Process (USPTO 20170216414)
By a News Reporter-Staff News Editor at Biotech Business Week A patent application by the inventors Tezel, Ahmet; Blanda, Wendy M.; Hughes, Patrick M.; Whitcup, Scott M.; Chang, James N.; Robinson, Michael R., filed on April 17, 2017, was made available online on August 10, 2017, according to news reporting originating from Washington, D.C., by N
8/21/17 - "Development of Masked Therapeutic Antibodies to Limit Off-Target Effects: Application to Anti-Egfr Antibodies" in Patent Application Approval...
"Development of Masked Therapeutic Antibodies to Limit Off- Target Effects: Application to Anti-Egfr Antibodies" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventors WILLIAMS, John C.; RODECK, Ulrich; DONALDSON, Joshua M.; KARI, Csaba, filed on February 22, 2017
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415